# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# **SCHEDULE 13G**

Under the Securities Exchange Act of 1934 (Amendment No. )\*

# **Evoke Pharma, Inc.**

(Name of Issuer)

Common Stock, \$0.0001 par value per share (Title of Class of Securities)

> 30049G104 (CUSIP Number)

July 20, 2016 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- a. 🛛 Rule 13d-1(b)
- b. 🛛 Rule 13d-1(c)
- c. 🛛 Rule 13d-1(d)
- \* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 8

# CUSIP No. 30049G104

1	Namas	of D	norting Descond				
1.	. Names of Reporting Persons.						
	Mitchell P. Kopin						
2.							
	(a) 🗆		b) $\Box$				
3.	B. SEC Use Only						
4.	4. Citizenship or Place of Organization						
	United States of America						
	Officed	5.	Sole Voting Power				
		5.					
Nu	mber of		0				
	Shares	6.	Shared Voting Power				
-	eficially						
	vned by		472,188				
	Each	7.	Sole Dispositive Power				
	porting Person						
	With:	8.	0 Shared Dispositive Power				
		0.	Silared Dispositive Fower				
			401,988				
9.	Aggrega	ate A	mount Beneficially Owned by Each Reporting Person				
			see Item 4)				
10.	Check i	f the	Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)				
11.	11. Percent of Class Represented by Amount in Row (9)						
	4.99% (see Item 4)						
12.	Type of	Rep	orting Person (See Instructions)				
	IN; HC						
	11, 110						

Page 2 of 8

# CUSIP No. 30049G104

	NT	( D	.' D				
1.	. Names of Reporting Persons.						
	Danial	р	A shor				
2.	Daniel B. Asher						
۷.	2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) □ (b) □						
	(u) <b></b>	(					
3.	. SEC Use Only						
4.	4. Citizenship or Place of Organization						
	ites of America						
		5.	Sole Voting Power				
Nu	mber of	6.	0				
-	Shares		Shared Voting Power				
	eficially						
	vned by Each	1	472,188				
	porting	7.	Sole Dispositive Power				
	Person		0				
	With:	8.	Shared Dispositive Power				
		0.					
			401,988				
9.	Aggrega	te A	mount Beneficially Owned by Each Reporting Person				
			ee Item 4)				
10.	Check if	the	Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)				
11.	Percent	of C	lass Represented by Amount in Row (9)				
	$4.000/(\cos 1 \tan 4)$						
12.	4.99% (see Item 4)						
12.	12. Type of Reporting Person (See Instructions)						
	IN; HC						
	,						

Page 3 of 8

# CUSIP No. 30049G104

	110.500					
1.	Names of Reporting Persons.					
	Intracoastal Capital LLC					
2.	. Check the Appropriate Box if a Member of a Group (See Instructions)					
	(a) 🗆	(	b) 🗆			
3.	SEC Use Only					
4.	4. Citizenship or Place of Organization					
	United	ites of America				
		5.	Sole Voting Power			
Nu	mber of		0			
5	Shares	6.	Shared Voting Power			
	neficially wned by		472,188			
	Each	7.	Sole Dispositive Power			
F	Reporting Person		0			
	With:	8.	Shared Dispositive Power			
			401,988			
9.	Aggregate Amount Beneficially Owned by Each Reporting Person					
			ee Item 4)			
10.	Check i	f the	Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)			
11.	1. Percent of Class Represented by Amount in Row (9)					
	4.99% (see Item 4)					
12.	2. Type of Reporting Person (See Instructions)					
	00					

Page 4 of 8

# Item 1.

(a) Name of Issuer

Evoke Pharma, Inc. (the "Issuer")

(b) Address of Issuer's Principal Executive Offices

505 Lomas Santa Fe Drive, Suite 270 Solana Beach, California 92075

#### Item 2.

(a) Name of Person Filing

(b) Address of Principal Business Office or, if none, Residence

(c) Citizenship

This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America ("**Mr**. **Kopin**"), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America ("**Mr. Asher**") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("**Intracoastal**" and together with Mr. Kopin and Mr. Asher, collectively the "**Reporting Persons**").

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as **Exhibit 1**, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

(d) Title of Class of Securities

Common stock, \$0.0001 par value per share, of the Issuer (the "Common Stock").

(e) CUSIP Number

30049G104

## Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

#### Item 4. Ownership.

(a) and (b):

(i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on July 20, 2016 (the "**SPA**") (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on July 20, 2016), each of the Reporting Persons may have been deemed to have beneficial ownership of 501,254 shares of Common Stock, and all such shares of Common Stock in the aggregate represented beneficial ownership of approximately 6.4% of the Common Stock, based on (1) 7,291,841 shares of Common Stock outstanding as of July 19, 2016 as reported to the Reporting Persons by the Issuer, plus (2) 501,254 shares of Common Stock that were to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes 375,941 shares of Common Stock issuable upon exercise of a warrant that was to be issued to Intracoastal at the closing of the transaction

Page 5 of 8

contemplated by the SPA (the "**Intracoastal Warrant**") because the Intracoastal Warrant contains a blocker provision under which the holder thereof does not have the right to exercise the Intracoastal Warrant to the extent that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 877,195 shares of Common Stock.

(ii) As of the close of business on July 27, 2016, each of the Reporting Persons may have been deemed to have beneficial ownership of 472,188 shares of Common Stock, which consisted of (i) 105,854 shares of Common Stock held by Intracoastal and (ii) 366,334 shares of Common Stock issuable upon exercise of the Intracoastal Warrant, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 4.99% of the Common Stock, based on (i) 7,291,841 shares of Common Stock outstanding as of July 19, 2016 as reported to the Reporting Persons by the Issuer, plus (2) 1,804,512 shares of Common Stock that were issued at the closing of the transaction contemplated by the SPA, plus (3) 366,334 shares of Common Stock issuable upon exercise of the Intracoastal Warrant. The foregoing excludes 9,607 shares of Common Stock issuable upon exercise of the Intracoastal Warrant because the Intracoastal Warrant contains a blocker provision under which the holder thereof does not have the right to exercise the Intracoastal Warrant to the extent that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 481,795 shares of Common Stock.

#### (C)

Number of shares as to which each Reporting Person has:

- (1) Sole power to vote or to direct the vote: 0.
- (2) Shared power to vote or to direct the vote: 472,188.
- (3) Sole power to dispose or to direct the disposition of 0.
- (4) Shared power to dispose or to direct the disposition of 401,988.

#### Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following 🗵.

### Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

- Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not applicable.
- Item 8. Identification and Classification of Members of the Group Not applicable.
- Item 9. Notice of Dissolution of Group

Not applicable.

#### Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

Page 6 of 8

# SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: July 27, 2016

/s/ Mitchell P. Kopin Mitchell P. Kopin

/s/ Daniel B. Asher Daniel B. Asher

Intracoastal Capital LLC

By: /s/ Mitchell P. Kopin Mitchell P. Kopin, Manager

Page 7 of 8

#### JOINT FILING AGREEMENT

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Date: July 27, 2016

/s/ Mitchell P. Kopin Mitchell P. Kopin

/s/ Daniel B. Asher Daniel B. Asher

Intracoastal Capital LLC

By: /s/ Mitchell P. Kopin Mitchell P. Kopin, Manager

Page 8 of 8